 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Atara Biotherapeutics, Inc. Nasdaq: ATRA, today announced the upcoming full release of new translational data and two-year open-label extension OLE clinical data from the study of ATA188 in progressive multiple sclerosis MS. The findings will be presented as an ePoster at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS taking place virtually October 13-15, 2021. The presentation includes n 